Synthetic gene circuits drive disease-fighting T cells

Marco L. Davila,Renier Brentjens

DOI: https://doi.org/10.1126/science.adt9921

IF: 56.9

2024-12-07

Science

Abstract:Immune cells can be programmed to deliver targeted therapies in models of brain and inflammatory disease

multidisciplinary sciences

What problem does this paper attempt to address?

Rapid discovery of synthetic DNA sequences to rewrite endogenous T cell circuits

Theodore L. Roth,P. Jonathan Li,Jasper F. Nies,Ruby Yu,Michelle L.T. Nguyen,Youjin Lee,Ryan Apathy,Anna Truong,Joseph Hiatt,David Wu,David N. Nguyen,Daniel Goodman,Jeffrey A. Bluestone,Kole Roybal,Eric Shifrut,Alexander Marson

DOI: https://doi.org/10.1101/604561

2019-04-12

Abstract:ABSTRACT Genetically-engineered immune cell therapies have been in development for decades 1–3 and recently have proven effective to treat some types of cancer 4 . CRISPR-based genome editing methods, enabling more flexible and targeted sequence integrations than viral transduction, have the potential to extend the clinical utility of cell therapies 5,6 . Realization of this potential depends on improved knowledge of how coding and non-coding sites throughout the genome can be modified efficiently and on improved methods to discover novel synthetic DNA sequences that can be introduced at targeted sites to enhance critical immune cell functions. Here, we developed improved guidelines for non-viral genome targeting in human T cells and a pooled discovery platform to identify synthetic genome modifications that enhance therapeutically-relevant cell functions. We demonstrated the breadth of targetable genomic loci by performing large knock-ins at 91 different genomic sites in primary human T cells, and established the power of flexible genome targeting by generating cells with Genetically Engineered Endogenous Proteins (GEEPs) that seamlessly integrate synthetic and endogenous genetic elements to alter signaling input, output, or regulatory control of genes encoding key immune receptors. Motivated by success in introducing synthetic circuits into endogenous sites, we then developed a platform to facilitate discovery of novel multi-gene sequences that reprogram both T cell specificity and function. We knocked in barcoded pools of large DNA sequences encoding polycistronic gene programs. High-throughput pooled screening of targeted knock-ins to the endogenous T cell receptor (TCR) locus revealed a transcriptional regulator and novel protein chimeras that combined with a new TCR specificity to enhance T cell responses in the presence of suppressive conditions in vitro and in vivo . Overall, these pre-clinical studies provide flexible tools to discover complex synthetic gene programs that can be written into targeted genome sites to generate more effective therapeutic cells.
Genetically engineered T cells for cancer immunotherapy

Dan Li,Xue Li,Wei-Lin Zhou,Yong Huang,Xiao Liang,Lin Jiang,Xiao Yang,Jie Sun,Zonghai Li,Wei-Dong Han,Wei Wang

DOI: https://doi.org/10.1038/s41392-019-0070-9

IF: 39.3

2019-01-01

Signal Transduction and Targeted Therapy

Abstract:T cells in the immune system protect the human body from infection by pathogens and clear mutant cells through specific recognition by T cell receptors (TCRs). Cancer immunotherapy, by relying on this basic recognition method, boosts the antitumor efficacy of T cells by unleashing the inhibition of immune checkpoints and expands adaptive immunity by facilitating the adoptive transfer of genetically engineered T cells. T cells genetically equipped with chimeric antigen receptors (CARs) or TCRs have shown remarkable effectiveness in treating some hematological malignancies, although the efficacy of engineered T cells in treating solid tumors is far from satisfactory. In this review, we summarize the development of genetically engineered T cells, outline the most recent studies investigating genetically engineered T cells for cancer immunotherapy, and discuss strategies for improving the performance of these T cells in fighting cancers.
Programming tissue-sensing T cells that deliver therapies to the brain

Milos S. Simic,Payal B. Watchmaker,Sasha Gupta,Yuan Wang,Sharon A. Sagan,Jason Duecker,Chanelle Shepherd,David Diebold,Psalm Pineo-Cavanaugh,Jeffrey Haegelin,Robert Zhu,Ben Ng,Wei Yu,Yurie Tonai,Lia Cardarelli,Nishith R. Reddy,Sachdev S. Sidhu,Olga Troyanskaya,Stephen L. Hauser,Michael R. Wilson,Scott S. Zamvil,Hideho Okada,Wendell A. Lim

DOI: https://doi.org/10.1126/science.adl4237

IF: 56.9

2024-12-07

Science

Abstract:To engineer cells that can specifically target the central nervous system (CNS), we identified extracellular CNS-specific antigens, including components of the CNS extracellular matrix and surface molecules expressed on neurons or glial cells. Synthetic Notch receptors engineered to detect these antigens were used to program T cells to induce the expression of diverse payloads only in the brain. CNS-targeted T cells that induced chimeric antigen receptor expression efficiently cleared primary and secondary brain tumors without harming cross-reactive cells outside of the brain. Conversely, CNS-targeted cells that locally delivered the immunosuppressive cytokine interleukin-10 ameliorated symptoms in a mouse model of neuroinflammation. Tissue-sensing cells represent a strategy for addressing diverse disorders in an anatomically targeted manner.

multidisciplinary sciences
A synthetic biology approach to engineering circuits in immune cells

Daniel Hoces,Jesús Miguens Blanco,Rogelio A. Hernández‐López,Jesús Miguens Blanco

DOI: https://doi.org/10.1111/imr.13244

2023-07-19

Immunological Reviews

Abstract:Summary A synthetic circuit in a biological system involves the designed assembly of genetic elements, biomolecules, or cells to create a defined function. These circuits are central in synthetic biology, enabling the reprogramming of cellular behavior and the engineering of cells with customized responses. In cancer therapeutics, engineering T cells with circuits have the potential to overcome the challenges of current approaches, for example, by allowing specific recognition and killing of cancer cells. Recent advances also facilitate engineering integrated circuits for the controlled release of therapeutic molecules at specified locations, for example, in a solid tumor. In this review, we discuss recent strategies and applications of synthetic receptor circuits aimed at enhancing immune cell functions for cancer immunotherapy. We begin by introducing the concept of circuits in networks at the molecular and cellular scales and provide an analysis of the development and implementation of several synthetic circuits in T cells that have the goal to overcome current challenges in cancer immunotherapy. These include specific targeting of cancer cells, increased T‐cell proliferation, and persistence in the tumor microenvironment. By harnessing the power of synthetic biology, and the characteristics of certain circuit architectures, it is now possible to engineer a new generation of immune cells that recognize cancer cells, while minimizing off‐target toxicities. We specifically discuss T‐cell circuits for antigen density sensing. These circuits allow targeting of solid tumors that share antigens with normal tissues. Additionally, we explore designs for synthetic circuits that could control T‐cell differentiation or T‐cell fate as well as the concept of synthetic multicellular circuits that leverage cellular communication and division of labor to achieve improved therapeutic efficacy. As our understanding of cell biology expands and novel tools for genome, protein, and cell engineering are developed, we anticipate further innovative approaches to emerge in the design and engineering of circuits in immune cells.

immunology
Synthetic cytokine circuits that drive T cells into immune-excluded tumors

Greg M Allen,Nicholas W Frankel,Nishith R Reddy,Hersh K Bhargava,Maia A Yoshida,Sierra R Stark,Megan Purl,Jungmin Lee,Jacqueline L Yee,Wei Yu,Aileen W Li,K Christopher Garcia,Hana El-Samad,Kole T Roybal,Matthew H Spitzer,Wendell A Lim

DOI: https://doi.org/10.1126/science.aba1624

IF: 56.9

2022-12-16

Science

Abstract:Chimeric antigen receptor (CAR) T cells are ineffective against solid tumors with immunosuppressive microenvironments. To overcome suppression, we engineered circuits in which tumor-specific synNotch receptors locally induce production of the cytokine IL-2. These circuits potently enhance CAR T cell infiltration and clearance of immune-excluded tumors, without systemic toxicity. The most effective IL-2 induction circuit acts in an autocrine and T cell receptor (TCR)- or CAR-independent manner, bypassing suppression mechanisms including consumption of IL-2 or inhibition of TCR signaling. These engineered cells establish a foothold in the target tumors, with synthetic Notch-induced IL-2 production enabling initiation of CAR-mediated T cell expansion and cell killing. Thus, it is possible to reconstitute synthetic T cell circuits that activate the outputs ultimately required for an antitumor response, but in a manner that evades key points of tumor suppression.
Enhancing cell‐based therapies with synthetic gene circuits responsive to molecular stimuli

Silvia Galvan,Ana P. Teixeira,Martin Fussenegger

DOI: https://doi.org/10.1002/bit.28770

IF: 3.8

2024-06-14

Biotechnology and Bioengineering

Abstract:Next‐generation cell‐based therapies require enhanced safety and spatiotemporal control, which can be ensured through the incorporation of synthetic gene switches. This review details recent developments in synthetic gene switches responsive to different molecular inputs and acting at the transcriptional, translational, and post‐translational levels. It also explores current perspectives of cell‐based therapies and the challenges facing clinical translation. Synthetic biology aims to contribute to the development of next‐generation patient‐specific cell‐based therapies for chronic diseases especially through the construction of sophisticated synthetic gene switches to enhance the safety and spatiotemporal controllability of engineered cells. Indeed, switches that sense and process specific cues, which may be either externally administered triggers or endogenous disease‐associated molecules, have emerged as powerful tools for programming and fine‐tuning therapeutic outputs. Living engineered cells, often referred to as designer cells, incorporating such switches are delivered to patients either as encapsulated cell implants or by infusion, as in the case of the clinically approved CAR‐T cell therapies. Here, we review recent developments in synthetic gene switches responsive to molecular stimuli, spanning regulatory mechanisms acting at the transcriptional, translational, and posttranslational levels. We also discuss current challenges facing clinical translation of cell‐based therapies employing these devices.

biotechnology & applied microbiology
Multidimensional control of therapeutic human cell function with synthetic gene circuits

Hui-Shan Li,Divya V Israni,Keith A Gagnon,Kok Ann Gan,Michael H Raymond,Jeffry D Sander,Kole T Roybal,J Keith Joung,Wilson W Wong,Ahmad S Khalil

DOI: https://doi.org/10.1126/science.ade0156

IF: 56.9

2022-12-16

Science

Abstract:Synthetic gene circuits that precisely control human cell function could expand the capabilities of gene- and cell-based therapies. However, platforms for developing circuits in primary human cells that drive robust functional changes in vivo and have compositions suitable for clinical use are lacking. Here, we developed synthetic zinc finger transcription regulators (synZiFTRs), which are compact and based largely on human-derived proteins. As a proof of principle, we engineered gene switches and circuits that allow precise, user-defined control over therapeutically relevant genes in primary T cells using orthogonal, US Food and Drug Administration-approved small-molecule inducers. Our circuits can instruct T cells to sequentially activate multiple cellular programs such as proliferation and antitumor activity to drive synergistic therapeutic responses. This platform should accelerate the development and clinical translation of synthetic gene circuits in diverse human cell types and contexts.
Clinically-driven design of synthetic gene regulatory programs in human cells

Divya V. Israni,Hui-Shan Li,Keith A. Gagnon,Jeffry D. Sander,Kole T. Roybal,J. Keith Joung,Wilson W. Wong,Ahmad S. Khalil

DOI: https://doi.org/10.1101/2021.02.22.432371

2021-02-23

Abstract:Abstract Synthetic biology seeks to enable the rational design of regulatory molecules and circuits to reprogram cellular behavior. The application of this approach to human cells could lead to powerful gene and cell-based therapies that provide transformative ways to combat complex diseases. To date, however, synthetic genetic circuits are challenging to implement in clinically-relevant cell types and their components often present translational incompatibilities, greatly limiting the feasibility, efficacy and safety of this approach. Here, using a clinically-driven design process, we developed a toolkit of programmable synthetic transcription regulators that feature a compact human protein-based design, enable precise genome-orthogonal regulation, and can be modulated by FDA-approved small molecules. We demonstrate the toolkit by engineering therapeutic human immune cells with genetic programs that enable titratable production of immunotherapeutics, drug-regulated control of tumor killing in vivo and in 3D spheroid models, and the first multi-channel synthetic switch for independent control of immunotherapeutic genes. Our work establishes a powerful platform for engineering custom gene expression programs in mammalian cells with the potential to accelerate clinical translation of synthetic systems.
Synthetic mammalian gene circuits for biomedical applications.

Haifeng Ye,Dominique Aubel,Martin Fussenegger

DOI: https://doi.org/10.1016/j.cbpa.2013.10.006

IF: 8.972

2013-01-01

Current Opinion in Chemical Biology

Abstract:•Synthetic biology strategies for disease therapy.•Synthetic gene circuits for treating metabolic disorders.•Synthetic logic circuits for cancer therapy.•Engineering synthetic circuits for immune-mediated therapy.
Genetic engineering of T cells for immunotherapy

Gavin I. Ellis,Neil C. Sheppard,James L. Riley

DOI: https://doi.org/10.1038/s41576-021-00329-9

IF: 59.581

2021-02-18

Nature Reviews Genetics

Abstract:Genetically engineered T cell immunotherapies have provided remarkable clinical success to treat B cell acute lymphoblastic leukaemia by harnessing a patient's own T cells to kill cancer, and these approaches have the potential to provide therapeutic benefit for numerous other cancers, infectious diseases and autoimmunity. By introduction of either a transgenic T cell receptor or a chimeric antigen receptor, T cells can be programmed to target cancer cells. However, initial studies have made it clear that the field will need to implement more complex levels of genetic regulation of engineered T cells to ensure both safety and efficacy. Here, we review the principles by which our knowledge of genetics and genome engineering will drive the next generation of adoptive T cell therapies.

genetics & heredity
A genome-scale screen for synthetic drivers of T cell proliferation

Mateusz Legut,Zoran Gajic,Maria Guarino,Zharko Daniloski,Jahan A Rahman,Xinhe Xue,Congyi Lu,Lu Lu,Eleni P Mimitou,Stephanie Hao,Teresa Davoli,Catherine Diefenbach,Peter Smibert,Neville E Sanjana

DOI: https://doi.org/10.1038/s41586-022-04494-7

IF: 64.8

Nature

Abstract:The engineering of autologous patient T cells for adoptive cell therapies has revolutionized the treatment of several types of cancer1. However, further improvements are needed to increase response and cure rates. CRISPR-based loss-of-function screens have been limited to negative regulators of T cell functions2-4 and raise safety concerns owing to the permanent modification of the genome. Here we identify positive regulators of T cell functions through overexpression of around 12,000 barcoded human open reading frames (ORFs). The top-ranked genes increased the proliferation and activation of primary human CD4+ and CD8+ T cells and their secretion of key cytokines such as interleukin-2 and interferon-γ. In addition, we developed the single-cell genomics method OverCITE-seq for high-throughput quantification of the transcriptome and surface antigens in ORF-engineered T cells. The top-ranked ORF-lymphotoxin-β receptor (LTBR)-is typically expressed in myeloid cells but absent in lymphocytes. When overexpressed in T cells, LTBR induced profound transcriptional and epigenomic remodelling, leading to increased T cell effector functions and resistance to exhaustion in chronic stimulation settings through constitutive activation of the canonical NF-κB pathway. LTBR and other highly ranked genes improved the antigen-specific responses of chimeric antigen receptor T cells and γδ T cells, highlighting their potential for future cancer-agnostic therapies5. Our results provide several strategies for improving next-generation T cell therapies by the induction of synthetic cell programmes.
Engineering Principles for Synthetic Biology Circuits in Cancer Immunotherapy

Ryan M Shih,Yvonne Y Chen,Ryan M. Shih,Yvonne Y. Chen

DOI: https://doi.org/10.1158/2326-6066.CIR-21-0769

IF: 10.1

2022-01-05

Cancer Immunology Research

Abstract:Recent advances in biomolecular engineering have led to novel cancer immunotherapies with sophisticated programmed functions, including chimeric antigen receptor (CAR) T cells that bind tumor-associated antigens (TAA) to direct coordinated immune responses. Extensive engineering efforts have been made to program not only CAR specificity, but also downstream pathways that activate molecular responses. Collectively, these efforts can be conceptualized as an immunotherapy circuit: TAAs bind the CAR as input signals; intracellular signaling cascades process the binding interactions into transcriptional and translational events; and those events program effector output functions. More simply, this sequence may be abstracted as input, processing, and output. In this review, we discuss the increasingly complex scene of synthetic-biology solutions in cancer immunotherapy and summarize recent work within the framework of immunotherapy circuits. In doing so, a toolbox of basic modular circuits may be established as a foundation upon which sophisticated solutions can be constructed to meet more complex problems. See related article on p. 5.

oncology,immunology
Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs

Nishith R. Reddy,Hasna Maachi,Yini Xiao,Milos S. Simic,Wei Yu,Yurie Tonai,Daniela A. Cabanillas,Ella Serrano-Wu,Philip T. Pauerstein,Whitney Tamaki,Greg M. Allen,Audrey V. Parent,Matthias Hebrok,Wendell A. Lim

DOI: https://doi.org/10.1126/science.adl4793

IF: 56.9

2024-12-07

Science

Abstract:Immune homeostasis requires a balance of inflammatory and suppressive activities. To design cells potentially useful for local immune suppression, we engineered conventional CD4 + T cells with synthetic Notch (synNotch) receptors driving antigen-triggered production of anti-inflammatory payloads. Screening a diverse library of suppression programs, we observed the strongest suppression of cytotoxic T cell attack by the production of both anti-inflammatory factors (interleukin-10, transforming growth factor–β1, programmed death ligand 1) and sinks for proinflammatory cytokines (interleukin-2 receptor subunit CD25). Engineered cells with bespoke regulatory programs protected tissues from immune attack without systemic suppression. Synthetic suppressor T cells protected transplanted beta cell organoids from cytotoxic T cells. They also protected specific tissues from unwanted chimeric antigen receptor (CAR) T cell cross-reaction. Synthetic suppressor T cells are a customizable platform to potentially treat autoimmune diseases, organ rejection, and CAR T cell toxicities with spatial precision.

multidisciplinary sciences
A Chimeric Conjugate of Antibody and Programmable DNA Nanoassembly Smartly Activates T Cells for Precise Cancer Cell Targeting

Rui Tang,Yu-Hao Fu,Bo Gong,Ying-Ying Fan,Hong-Hui Wang,Yan Huang,Zhou Nie,Ping Wei

DOI: https://doi.org/10.1002/anie.202205902

2022-01-01

Angewandte Chemie

Abstract:Synthetically directing T-cells against tumors emerges as a promising strategy in immunotherapy, while it remains challenging to smartly engage T cells with tunable immune response. Herein, we report an intelligent molecular platform to engineer T-cell recognition for selective activation to potently kill cancer cells. To this end, we fabricated a hybrid conjugate that uses a click-type DNA-protein conjugation to equip the T cell-engaging antibody with two distinct programmable DNA nanoassemblies. By integrating multiple aptameric antigen-recognitions within a dynamic DNA circuit, we achieved combinatorial recognition of triple-antigens on cancer cells for selective T-cell activation after high-order logic operation. Moreover, by coupling a DNA nanostructure, we precisely defined the valence of the antigen-binding aptamers to tune avidity, realizing effective tumor elimination in vitro and in vivo. Together, we present a versatile and programmable strategy for synthetic immunotherapy.
Precise tumor immune rewiring via synthetic CRISPRa circuits gated by concurrent gain/loss of transcription factors

Yafeng Wang,Guiquan Zhang,Qingzhou Meng,Shisheng Huang,Panpan Guo,Qibin Leng,Lingyun Sun,Geng Liu,Xingxu Huang,Jianghuai Liu

DOI: https://doi.org/10.1038/s41467-022-29120-y

IF: 16.6

2022-01-01

Nature Communications

Abstract:Reinvigoration of antitumor immunity has recently become the central theme for the development of cancer therapies. Nevertheless, the precise delivery of immunotherapeutic activities to the tumors remains challenging. Here, we explore a synthetic gene circuit-based strategy for specific tumor identification, and for subsequently engaging immune activation. By design, these circuits are assembled from two interactive modules, i.e., an oncogenic TF-driven CRISPRa effector, and a corresponding p53-inducible off-switch (NOT gate), which jointly execute an AND-NOT logic for accurate tumor targeting. In particular, two forms of the NOT gate are developed, via the use of an inhibitory sgRNA or an anti-CRISPR protein, with the second form showing a superior performance in gating CRISPRa by p53 loss. Functionally, the optimized AND-NOT logic circuit can empower a highly specific and effective tumor recognition/immune rewiring axis, leading to therapeutic effects in vivo. Taken together, our work presents an adaptable strategy for the development of precisely delivered immunotherapy.
Programmable synthetic receptors: the next-generation of cell and gene therapies.

Fei Teng,Tongtong Cui,Li Zhou,Qingqin Gao,Qi Zhou,Wei Li

DOI: https://doi.org/10.1038/s41392-023-01680-5

IF: 39.3

2024-01-01

Signal Transduction and Targeted Therapy

Abstract:Cell and gene therapies hold tremendous promise for treating a range of difficult-to-treat diseases. However, concerns over the safety and efficacy require to be further addressed in order to realize their full potential. Synthetic receptors, a synthetic biology tool that can precisely control the function of therapeutic cells and genetic modules, have been rapidly developed and applied as a powerful solution. Delicately designed and engineered, they can be applied to finetune the therapeutic activities, i.e., to regulate production of dosed, bioactive payloads by sensing and processing user-defined signals or biomarkers. This review provides an overview of diverse synthetic receptor systems being used to reprogram therapeutic cells and their wide applications in biomedical research. With a special focus on four synthetic receptor systems at the forefront, including chimeric antigen receptors (CARs) and synthetic Notch (synNotch) receptors, we address the generalized strategies to design, construct and improve synthetic receptors. Meanwhile, we also highlight the expanding landscape of therapeutic applications of the synthetic receptor systems as well as current challenges in their clinical translation.
Reprogramming-based gene therapy promotes anti-tumor immunity in vivo

Chiara Anania

DOI: https://doi.org/10.1038/s41588-024-01956-8

IF: 30.8

2024-10-11

Nature Genetics

Abstract:Cancer immunotherapy induces a tumor antigen-specific T lymphocyte response that kills tumor cells. Dendritic cells, specifically conventional type 1 dendritic cells (cDC1s), have a crucial role in antigen presentation, making them an important cell type for immunotherapy. Tumor cell reprogramming into cDC1-like cells by the transcription factors PU.1, IRF8 and BATF2 (PIB) results in robust T cell activation in vitro. Ascic et al. demonstrate that PIB-mediated cDC1 reprogramming triggers anti-tumor immunity and hampers tumor growth in melanoma mouse models. Moreover, it remodels the tumor microenvironment by increasing memory and stem-like T cell infiltration while reducing the exhausted population. Single-cell transcriptomics reveals expansion of the CD4 + T cell population, supporting PIB-mediated immunity. Among the gene therapy delivery strategies tested, adenoviral vectors show robust tumor transduction and reprogramming in situ, triggering an efficient T cell response in lymph nodes and tumors. As a result, mice remain tumor free and resistant to metastatic spreading. Importantly, PIB overexpression in human xenografts and tumor spheroids also induces cDC1 reprogramming and immunogenicity independently of immunosuppression. This study introduces a cDC1 reprogramming-based gene therapy approach that promotes long-term, safe and efficient anti-tumor immunity. Original reference: Science https://doi.org/10.1126/science.adn9083 (2024)

genetics & heredity
[Smart Therapeutics Based on Synthetic Gene Circuits].

Shuguang Peng,Zhen Xie

DOI: https://doi.org/10.13345/j.cjb.160425

2017-01-01

Abstract:Synthetic biology has an important impact on biology research since its birth. Applying the thought and methods that reference from electrical engineering, synthetic biology uncovers many regulatory mechanisms of life systems, transforms and expands a series of biological components. Therefore, it brings a wide range of biomedical applications, including providing new ideas for disease diagnosis and treatment. This review describes the latest advances in the field of disease diagnosis and therapy based on mammalian cell or bacterial synthetic gene circuits, and provides new ideas for future smart therapy design.
Targeted gene delivery systems for T-cell engineering

DOI: https://doi.org/10.1007/s13402-024-00954-6

IF: 7.051

2024-05-17

Cellular Oncology

Abstract:T lymphocytes are indispensable for the host systems of defense against pathogens, tumors, and environmental threats. The therapeutic potential of harnessing the cytotoxic properties of T lymphocytes for antigen-specific cell elimination is both evident and efficacious. Genetically engineered T-cells, such as those employed in CAR-T and TCR-T cell therapies, have demonstrated significant clinical benefits in treating cancer and autoimmune disorders. However, the current landscape of T-cell genetic engineering is dominated by strategies that necessitate in vitro T-cell isolation and modification, which introduce complexity and prolong the development timeline of T-cell based immunotherapies. This review explores the complexities of gene delivery systems designed for T cells, covering both viral and nonviral vectors. Viral vectors are known for their high transduction efficiency, yet they face significant limitations, such as potential immunogenicity and the complexities involved in large-scale production. Nonviral vectors, conversely, offer a safer profile and the potential for scalable manufacturing, yet they often struggle with lower transduction efficiency. The pursuit of gene delivery systems that can achieve targeted gene transfer to T cell without the need for isolation represents a significant advancement in the field. This review assesses the design principles and current research progress of such systems, highlighting the potential for in vivo gene modification therapies that could revolutionize T-cell based treatments. By providing a comprehensive analysis of these systems, we aim to contribute valuable insights into the future development of T-cell immunotherapy.

oncology,pathology,cell biology
Synthetic Therapeutic Gene Circuits in Mammalian Cells

Haifeng Ye,Martin Fussenegger

DOI: https://doi.org/10.1016/j.febslet.2014.05.003

2014-01-01

FEBS Letters

Abstract:In the emerging field of synthetic biology, scientists are focusing on designing and creating functional devices, systems, and organisms with novel functions by engineering and assembling standardised biological building blocks. The progress of synthetic biology has significantly advanced the design of functional gene networks that can reprogram metabolic activities in mammalian cells and provide new therapeutic opportunities for future gene- and cell-based therapies. In this review, we describe the most recent advances in synthetic mammalian gene networks designed for biomedical applications, including how these synthetic therapeutic gene circuits can be assembled to control signalling networks and applied to treat metabolic disorders, cancer, and immune diseases. We conclude by discussing the various challenges and future prospects of using synthetic mammalian gene networks for disease therapy. (C) 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Synthetic gene circuits drive disease-fighting T cells

Rapid discovery of synthetic DNA sequences to rewrite endogenous T cell circuits

Genetically engineered T cells for cancer immunotherapy

Programming tissue-sensing T cells that deliver therapies to the brain

A synthetic biology approach to engineering circuits in immune cells

Synthetic cytokine circuits that drive T cells into immune-excluded tumors

Enhancing cell‐based therapies with synthetic gene circuits responsive to molecular stimuli

Multidimensional control of therapeutic human cell function with synthetic gene circuits

Clinically-driven design of synthetic gene regulatory programs in human cells

Synthetic mammalian gene circuits for biomedical applications.

Genetic engineering of T cells for immunotherapy

A genome-scale screen for synthetic drivers of T cell proliferation

Engineering Principles for Synthetic Biology Circuits in Cancer Immunotherapy

Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs

A Chimeric Conjugate of Antibody and Programmable DNA Nanoassembly Smartly Activates T Cells for Precise Cancer Cell Targeting

Precise tumor immune rewiring via synthetic CRISPRa circuits gated by concurrent gain/loss of transcription factors

Programmable synthetic receptors: the next-generation of cell and gene therapies.

Reprogramming-based gene therapy promotes anti-tumor immunity in vivo

[Smart Therapeutics Based on Synthetic Gene Circuits].

Targeted gene delivery systems for T-cell engineering

Synthetic Therapeutic Gene Circuits in Mammalian Cells